Rizatriptan 5 mg for the Acute Treatment of Migraine in Adolescents: Results From a Double‐Blind, Single‐Attack Study and Two Open‐Label, Multiple‐Attack Studies

Abstract

Rizatriptan 5 mg was not more effective than placebo in the treatment of a single migraine attack in adolescents, but appeared to be more effective than standard care for treating multiple attacks occurring over 1 year in these patients. Rizatriptan 5 mg was well tolerated in adolescents during short-term and long-term use.